Christine G Charon

USPTO Granted Patents = 28 (Patent Applications = 2)

CIPO Patents = 11 (Patent Applications = 2)

EPO Patents = 23 (Patent Applications = 18)

Average Co-Inventor Count = 5.2

ph-index = 1

Forward Citations = 8(Granted Patents)

Location History:

Gometz-le-Chatel, FR (2012 - 2017)
Gometz le Chantel, FR (2019)
Gometz-le-Châtel, FR (2016 - 2022)

Company Filing History:

Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft MIT Beschraenkter Haftung

patents

Years Active: 2012-2022

Loading Chart...

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11369595 - Use of tryptophan metabolites for treating muscle atrophy (2022-06-28),

2. 10350184 - Derivatives used in the treatment of muscle atrophy (2019-07-16),

3. 9777015 - Useful thiophene derivatives in the treatment of diabetes (2017-10-03),

4. 9381191 - Imidazopyridine derivatives useful in treating diabetes (2016-07-05),

5. 9365584 - Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof (2016-06-14),

6. 9284329 - Thienopyridone derivatives useful as activators of AMPK (2016-03-15),

7. 9233937 - Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones (2016-01-12),

8. 9102632 - Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes (2015-08-11),

9. 8835634 - Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes (2014-09-16),

10. 8815859 - Substituted pyrazin-2-ones and substituted 5,6,7,8-tetrahydroquinoxalin-2-ones and methods of use thereof (2014-08-26),

11. 8642617 - Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes (2014-02-04),

12. 8637522 - Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes (2014-01-28),

13. 8609689 - Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes (2013-12-17),

14. 8604202 - Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators (2013-12-10),

15. 8586577 - Diazepane acetamide derivatives as selective 11B-HSD1 inhibitors (2013-11-19),

Title: The Innovations of Christine G Charon in Muscle Atrophy Treatment

Introduction: Christine G Charon, based in Gometz le Chatel, France, is a notable inventor with an impressive portfolio of 28 patents. Her work primarily focuses on the treatment and prevention of muscle atrophy, showcasing her dedication to advancing medical science through innovative solutions.

Latest Patents: Among Christine's latest patents is the invention addressing the use of tryptophan metabolites for treating muscle atrophy. This invention includes a variety of tryptophan metabolites such as kynurenic acid and quinolinic acid and is designed for preventing muscle loss and promoting muscle growth, particularly in mammals engaged in physical exercise. Another significant patent involves oxime and alkoxy derivatives that serve as medicaments for treating and preventing muscle atrophy and promoting muscle growth. Both inventions emphasize the importance of maintaining muscle mass and quality, especially in aging populations and those experiencing recovery after muscle loss.

Career Highlights: Christine has made significant contributions to the pharmaceutical field, particularly during her tenure at Merck Patent GmbH and Metabrain Research. Her innovative approach has helped pave the way for new treatments addressing muscle atrophy, a condition that poses significant challenges in a variety of health scenarios.

Collaborations: Throughout her career, Christine has collaborated with esteemed coworkers, including Micheline R Kergoat and Samer Elbawab. These partnerships have enhanced her research and contributed to her success in developing effective treatments for muscle-related conditions.

Conclusion: Christine G Charon stands out in the realm of medical innovation, reflecting her commitment to addressing muscle atrophy through advanced research and patenting significant inventions. Her work not only helps improve the quality of life for many but also establishes a foundation for future innovations in the field.

This text is generated by artificial intelligence and may not be accurate.